Life Sciences

  • February 04, 2026

    Fertility Clinic Says Doctors Lured Staff To New Practice

    The owners of a Massachusetts fertility clinic say three doctors left to start their own practice and repeatedly violated a non-solicitation agreement to "raid" its staff, according to a complaint filed in state court.

  • February 04, 2026

    Ex-Hogan Lovells Regulatory Atty Moves To Honigman In DC

    An attorney specializing in guiding life sciences companies through the U.S. Food and Drug Administration's regulatory process has moved her practice to Honigman LLP's Washington, D.C., office after more than 11 years with Hogan Lovells.

  • February 04, 2026

    Drugmaker Claims Stake In La. Mail-Order Abortion Meds Row

    An abortion medication manufacturer asserted its right Wednesday to defend mifepristone, moving to intervene in a federal lawsuit over mail-order abortion medication brought by Louisiana alleging that regulators violated federal law by removing an in-person dispensing requirement for the drug.

  • February 04, 2026

    Express Scripts Makes 'Fundamental Changes' In FTC Deal

    Express Scripts on Wednesday agreed to what the Federal Trade Commission called a "landmark settlement" promising major changes to its drug formulary practices, allowing the company to duck out of a case accusing all three of the country's largest pharmacy benefit managers of inflating insulin prices through rebate schemes.

  • February 03, 2026

    ImmunityBio Stockholder Targets Soon-Shiong In Chancery

    The Delaware Chancery Court on Tuesday heard arguments over whether biotech billionaire Patrick Soon-Shiong and ImmunityBio Inc.'s board breached their fiduciary duties by approving insider financing that allegedly allowed him to secure equity at deeply discounted prices as the company neared regulatory approval for its lead cancer drug.

  • February 03, 2026

    Squires And Stewart's Patent Office, By The Numbers

    The U.S. Patent and Trademark Office has seen sweeping changes under Director John Squires and Deputy Director Coke Morgan Stewart, ranging from pro-patent owner policies at the Patent Trial and Appeal Board to employment shake-ups that have prompted departures from the agency.

  • February 03, 2026

    Medtronic's Bundling Isn't Anticompetitive, Prof Tells Jury

    A University of Chicago economics professor testified Tuesday in a California federal trial over antitrust claims against Medtronic, saying its practice of bundling its advanced bipolar devices for sales with other products isn't anticompetitive but is actually a very common American practice used by the likes of McDonald's and Costco. 

  • February 03, 2026

    Masimo Investors' $34M Deal In Revenue Suit Gets Initial OK

    Masimo Corp. and its investors have received initial approval of a $33.8 million deal to settle claims that the medical and audio device company based its sales and revenue projections on unrealistic expectations for demand.

  • February 03, 2026

    Trump Admin Sued Over 'Pay-To-Play' Gold Card Program

    Immigrants and an academic professionals union filed suit Tuesday to block President Donald Trump's "gold card" visa program, telling a D.C. federal court that the "pay-to-play" program unlawfully takes visas away from professionals the existing employment-based visa system prioritizes.

  • February 03, 2026

    Medical Transport Co. Misclassified Drivers, Suit Says

    A company that transports radioactive medical materials misclassified drivers as independent contractors, leading to minimum wage and overtime violations, according to a proposed class and collective action filed in Florida federal court.

  • February 03, 2026

    Novartis, Sandoz Face New Generic-Drug Price-Fixing Suit

    Adding to sprawling antitrust litigation against pharmaceutical giants, 42 states and territories sued Novartis AG, Sandoz AG and other drug companies in Connecticut federal court Monday, alleging that the companies colluded for years to fix prices and control markets for generic drugs.

  • February 03, 2026

    Pharma Co. Stole Secrets For LSD Medical Trials, Suit Says

    A clinical trial services company is suing Definium Therapeutics Inc. in Delaware federal court, alleging that it stole trade secrets during Phase 2 trials of LSD treatments for psychiatric disorders, then passed those secrets on to a rival services company for Phase 3 trials.

  • February 03, 2026

    Amway Looks To Sidestep Gut Drink Trademark Fight In NC

    Multi-level marketing giant Amway is seeking an early exit from a trademark infringement suit brought by a supplement maker in North Carolina, saying it has no ties to the Tar Heel state sufficient to be dragged into court there.

  • February 03, 2026

    Alston & Bird Adds Healthcare Regulatory Pro From Goodwin

    Alston & Bird LLP has added a healthcare regulatory attorney previously with Goodwin Procter LLP as a partner in Chicago, the firm announced Tuesday.

  • February 02, 2026

    Wheeling & Appealing: The Latest Must-Know Appellate Action

    What happened to a GOP donor's $250,000 Swiss watch? Can cigarette warnings show jarring medical images? Will a circuit split of "far-reaching importance" for arbitration get even wider? That's a taste of the oral argument menu we'll help you digest in this preview of February's top appellate action.

  • February 02, 2026

    'Terumo Knew' Of Dangerous Emissions, Jury Told

    A pollution expert witness told a Colorado jury Monday in the latest trial over Terumo's alleged emissions of toxic ethylene oxide that the medical sterilizer was fully aware of the community emissions and their danger.

  • February 02, 2026

    'Star Trek'-Citing Judge Says Moderna Can't Ax $5B Vax IP Suit

    Moderna Inc. will have to face most of a rival mRNA vaccine developer's $5 billion patent suit over the company's COVID-19 vaccines at a trial in Delaware, a federal judge ruled on Monday, invoking "Star Trek" in a summary judgment order that left issues like patent invalidity up to the jury.

  • February 02, 2026

    Monthly Merger Review Snapshot

    U.S. enforcers reached three new merger settlements, while the Federal Trade Commission successfully blocked a $945 million heart valve deal and lodged an appeal for its case targeting Meta's past acquisitions.

  • February 02, 2026

    PTAB Sinks Samsung Challenge To Ouraring Patent

    The Patent Trial and Appeal Board has shot down Samsung Electronics Co. Ltd.'s challenge to an Ouraring Inc. smart ring patent amid an ongoing legal dispute that has spanned the board, federal district court and the U.S. International Trade Commission.

  • February 02, 2026

    1st Circ. Judge Wary Of Boston Bid To Revive PBM Opioid Suit

    The city of Boston faced pushback from a First Circuit judge on Monday as it argued it didn't miss its window to sue pharmacy benefit managers for their alleged role in the opioid epidemic.

  • February 02, 2026

    DLA Piper Adds Ex-Cooley Atty To Lead N. Calif. Practice

    DLA Piper announced Monday that it has added the former global chair of Cooley LLP's digital health group to lead its Northern California corporate and securities practice and bolster its capacity to advise life sciences and technology companies on transactions and other matters.

  • February 02, 2026

    Mintz Adds Winston & Strawn ITC Practice Co-Leader In DC

    Mintz Levin Cohn Ferris Glovsky and Popeo PC has grown its Washington, D.C., office by bringing a Winston & Strawn LLP equity partner as its International Trade Commission practice co-chair, strengthening the firm's intellectual property services with a patent litigator with two decades of experience.

  • February 02, 2026

    Bausch, Lannett To Pay $17.9M In Drug Price-Fixing Deal

    Lannett Company Inc., Bausch Health US LLC and Bausch Health America Inc. will pay $17.85 million to settle allegations by 48 states and territories that they conspired to fix prices for generic drugs, according to a motion filed Monday seeking preliminary approval of the deal.

  • January 30, 2026

    3rd Circ. Preview: Privacy Issues Top Feb. Argument Lineup

    Issues involving privacy feature prominently on the Third Circuit's February oral argument schedule, with panels set to hear a dispute regarding an optometry business's duty to protect private data belonging to third-party customers, and a case over whether the city of Philadelphia can be sued by a mother after a police officer shared images of her son's death from the scene where he committed suicide.

  • January 30, 2026

    CBD Cos. Say They're Wrong Defendants In Kratom Suit

    Shaman Botanicals LLC and CBD American Shaman LLC are urging a California federal judge to throw out claims that they mislead consumers by failing to warn them that Soma Kratom products are dangerous and addictive, saying they're not affiliated with Soma Kratom in the first place.

Expert Analysis

  • Series

    Preaching Makes Me A Better Lawyer

    Author Photo

    Becoming a Gospel preacher has enhanced my success as a trial lawyer by teaching me the importance of credibility, relatability, persuasiveness and thorough preparation for my congregants, the same skills needed with judges and juries in the courtroom, says Reginald Harris at Stinson.

  • A Look At Middlemen Fees In 340B Drug Discount Program

    Author Photo

    A U.S. Senate committee's recent hearing on the Section 340B drug discount program, along with statistical analysis of payment amounts, contribute to a growing consensus that middlemen fees are too high, say William Sarraille at the University of Maryland, and Shanyue Zeng and Rory Martin at IQVIA.

  • How Large Patent Damages Awards Actually Play Out

    Author Photo

    Most large verdicts in patent infringement cases are often overturned or reduced on appeal, implying that the Federal Circuit is serving its intended purpose of correcting outlier outcomes, and that the figures that catch headlines and dominate policy debates may misrepresent economic realities, says Bowman Heiden at Berkeley School of Law.

  • Series

    Law School's Missed Lessons: Practicing Client-Led Litigation

    Author Photo

    New litigators can better help their corporate clients achieve their overall objectives when they move beyond simply fighting for legal victory to a client-led approach that resolves the legal dispute while balancing the company's competing out-of-court priorities, says Chelsea Ireland at Cohen Ziffer.

  • Navigating 2025's Post-Grant Proceeding Shakeups

    Author Photo

    Extensive changes to the U.S. Patent Trial and Appeal Board's post-grant proceedings this year, including the new settled expectations factor and revitalization of Fintiv factors, require petitioners and patent owners alike to be mindful when selecting patents to assert and challenge, say attorneys at Quinn Emanuel.

  • Series

    The Law Firm Merger Diaries: How To Build On Cultural Fit

    Author Photo

    Law firm mergers should start with people, then move to strategy: A two-level screening that puts finding a cultural fit at the pinnacle of the process can unearth shared values that are instrumental to deciding to move forward with a combination, says Matthew Madsen at Harrison.

  • Latisse Ruling's Lessons On Avoiding Chemical Patent Pitfalls

    Author Photo

    The Federal Circuit's decision in Duke v. Sandoz, reversing a $39 million infringement claim for selling a generic Latisse product, reinforces a fundamental truth in chemical patent strategy: Broad genus claims rarely survive without clear evidence of possession of specific embodiments, says Kimberly Vines at Stites & Harbison.

  • Considerations When Invoking The Common-Interest Privilege

    Author Photo

    To successfully leverage the common-interest doctrine in a multiparty transaction or complex litigation, practitioners should be able to demonstrate that the parties intended for it to apply, that an underlying privilege like attorney-client has attached, and guard against disclosures that could waive privilege and defeat its purpose, say attorneys at DLA Piper.

  • Series

    The Law Firm Merger Diaries: Making The Case To Combine

    Author Photo

    When making the decision to merge, law firm leaders must factor in strategic alignment, cultural compatibility and leadership commitment in order to build a compelling case for combining firms to achieve shared goals and long-term success, says Kevin McLaughlin at UB Greensfelder.

  • Key Risks For Cos. As MAHA Influences Food Regulation

    Author Photo

    As the Make America Healthy Again movement alters state and federal legislative and regulatory priorities, measures targeting ultra-processed foods, front-of-package labeling requirements and restrictions on schools are creating new compliance and litigation risks for food and beverage manufacturers, pharmaceutical companies, retailers and digital advertisers, say attorneys at Kelley Drye.

  • State AGs May Extend Their Reach To Nat'l Security Concerns

    Author Photo

    Companies with foreign supply-chain risk exposure need a comprehensive risk-management strategy to address a growing trend in which state attorneys general use broadly written state laws to target conduct that may not violate federal regulations, but arguably constitutes a national security threat, say attorneys at Wiley.

  • Opinion

    Despite Deputy AG Remarks, DOJ Can't Sideline DC Bar

    Author Photo

    Deputy Attorney General Todd Blanche’s recent suggestion that the D.C. Bar would be prevented from reviewing misconduct complaints about U.S. Department of Justice attorneys runs contrary to federal statutes, local rules and decades of case law, and sends the troubling message that federal prosecutors are subject to different rules, say attorneys at HWG.

  • Key Strategies For Supplement Cos. Facing Lead Risks

    Author Photo

    In the wake of a recent Consumer Reports article detailing dangerously high levels of lead in many popular protein powders, supplement companies face increased litigation, rising enforcement risks and reputational harm — underscoring the need to monitor supply chains, test ingredients and understand labeling standards, say attorneys at Husch Blackwell.

  • From Bank Loans To Private Credit: Tips For Making The Shift

    Author Photo

    The relationship between private credit and syndicated bank deals will evolve as the private market continues to grow, introducing new challenges for borrowers comparing financing options, particularly pertaining to loan documentation and working capital, say attorneys at Haynes Boone.

  • 3 Takeaways From FDA Cell And Gene Therapy Draft Guidance

    Author Photo

    The U.S. Food and Drug Administration recently published draft guidance documents that sketch the clearest picture yet of the evolving regulatory framework for cell and gene therapies, reflecting an agency that is increasingly comfortable with flexible, science-driven approaches that extend beyond clinical trial models, say attorneys at MoFo.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.